- ticket title
- Dev Patel seems to have found his new partner in sexy Nargis Fakhri
- Sprinklr, brainchild of Indian American entrepreneur Ragy Thomas, surpasses $1 billion valuation
- Risa Realty to showcase prime real estate properties in India at shows in Virginia, New Jersey
- In high-tech Karnataka Kannada language to be the instrument of teaching in schools
- NYPD police officer racially abuses, threatens Uber driver of South Asian origin
Koti is a researcher at Queen’s University.
WASHINGTON, DC: Queen’s University cancer researcher Madhuri Koti has discovered a breakthrough biomarker that will help lead to better predictions of the success of chemotherapy in ovarian cancer patients.
Biomarkers are an indicator of a biological state or condition, and Koti’s discovery could lead to better treatment options in the fight against ovarian cancer, according to a press release by the university.
“Recent successes in harnessing the immune system to combat cancer are evidence for the significant roles of a cancer patient’s immune responses in fighting cancer,” explains Koti. “Many of these success are based on boosting anti-cancer immunity via different therapies. Such therapies would prove to be most effective when coupled with markers predicting a patient’s eventual response to a specific therapy.”
Koti conducted the study in retrospective cohorts of over 200 ovarian cancer patients. The study utilized a combination of recent cutting-edge and more established detection technologies for identifying such markers. Initial discovery of these markers was made in frozen tumor tissues accrued from tumor banks such as the Ontario Tumor Bank and the Ottawa Health Research Institute and Gynecology-Oncology and Pathology services of the CHUMHospital Notre-Dame, Montreal.
Phase II validations are currently under way in retrospective cohorts of over 500 ovarian cancer patient tumors accrued from the Terry Fox Research Institute-Ovarian Cancer Canada partnered, Canadian Ovarian Experimental Unified Resource.
A major impact of this discovery is that these novel markers, when used at the time of treatment initiation in the specific type of ovarian cancer patient, will help gynecologic oncologists make decisions on additional treatment needed in these patients, thus increasing the potential for patient survival.
Ovarian cancer leads to approximately 152,000 deaths among women worldwide each year, making it a leading cause of gynecological cancer related deaths in women.
Koti’s findings were published recently in the British Journal of Cancer.
Warning: require_once(/homepages/30/d221447157/htdocs/GIN_NEW/wp-content/themes/news-maxx-1.0.1/footer.php): failed to open stream: Permission denied in /homepages/30/d221447157/htdocs/GIN_NEW/wp-includes/template.php on line 684
Fatal error: require_once(): Failed opening required '/homepages/30/d221447157/htdocs/GIN_NEW/wp-content/themes/news-maxx-1.0.1/footer.php' (include_path='.:/usr/lib/php5.5') in /homepages/30/d221447157/htdocs/GIN_NEW/wp-includes/template.php on line 684